A novel orally active Group 2 metabotropic glutamate receptor agonist
- 1 April 1997
- journal article
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 8 (6) , 1463-1465
- https://doi.org/10.1097/00001756-199704140-00027
Abstract
NON-SPECIFIC metabotropic glutamate receptor (mGluR) agonists have previously been shown to potentiate responses of spinal neurones to ionotropic glutamate receptor agonists. In this study we show that LY354740, which is a highly selective Group 2 mGluR agonist with nanomolar potency in vitro, also mimics the above effects following local ejection on spinal neurones in vivo, an action which is blocked by a Group 2 antagonist. Despite its polar nature, LY354740 is also active given either by the i.v. or the oral route (2.5–20 mg/kg) and thus will be a useful agent for investigating the role of Group 2 mGluRs both physiologically and clinically.Keywords
This publication has 4 references indexed in Scilit:
- Metabotropic glutamate receptors: potential drug targetsDrug Discovery Today, 1996
- Pharmacology of metabotropic glutamate receptor-mediated enhancement of responses to excitatory and inhibitory amino acids on rat spinal neurones in vivoNeuropharmacology, 1995
- The metabotropic glutamate receptors: Structure and functionsNeuropharmacology, 1995
- Molecular Diversity of Glutamate Receptors and Implications for Brain FunctionScience, 1992